Sensible Bio operates a cell-based mRNA design and manufacturing platform to produce pure mRNA therapeutics. This approach overcomes limitations of synthetic mRNA by yielding products with low immunogenicity. The platform enables a new paradigm for design-based biology in therapeutic development.
Funding
$4.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PVZVFounders
Product
Problem
Current mRNA manufacturing methods face limitations in producing non-immunogenic, pure, and highly functional mRNA therapeutics and vaccines, hindering the full potential of mRNA medicines. Traditional in vitro transcription-based mRNA production struggles with scalability and cost-efficiency.
Solution
Sensible Biotechnologies is developing a cell-based platform for the production of mRNA therapeutics and vaccines, designed to overcome the limitations of existing manufacturing techniques. The company's novel biomanufacturing infrastructure aims to produce non-immunogenic, pure, and highly functional mRNA. By leveraging an in vivo microbial mRNA manufacturing platform, Sensible seeks to enhance global biosecurity and improve the efficiency of mRNA medicine development, offering an alternative to conventional in vitro methods. This approach focuses on creating a more scalable and cost-efficient production process for high-quality mRNA.
Target Audience
The primary target audience includes biopharmaceutical companies and research institutions involved in the development of mRNA therapeutics and vaccines.
Features
- Cell-based mRNA production platform
- In vivo microbial mRNA manufacturing
- Production of non-immunogenic mRNA
- High-purity mRNA manufacturing
- Scalable mRNA production process
- Cost-efficient mRNA manufacturing